Overview
Français
ABSTRACT
Hybrid nanoparticles (gold, silica and iron oxide based nanoparticles, quantum dots) with a size inferior to 10 nm for applications in oncology will be described in this article. Hybrid nanoparticles can be used as imaging or therapeutic agent for detection and/or therapy of tumors. They display several advantages in comparison with molecular agents : better signal per object, the possibility to combine many functionalities for imaging and/or therapy and the capacity to target the tumor in combination with an adapted biodistribution and a relatively fast renal elimination.
Read this article from a comprehensive knowledge base, updated and supplemented with articles reviewed by scientific committees.
Read the articleAUTHORS
-
Charles TRUILLET: Doctoral engineer - Institut Lumière Matière, UMR 5306, Université Lyon 1 – CNRS, Université de Lyon, Villeurbanne cedex, France
-
François LUX: Senior Lecturer - Institut Lumière Matière, UMR 5306, Université Lyon 1 – CNRS, Université de Lyon, Villeurbanne cedex, France
-
Stéphane ROUX: Professor - Institut UTINAM, UMR 6213, CNRS – Université de Franche-Comté, Besançon, France
-
Pascal PERRIAT: Professor - Matériaux Ingénierie et Science, UMR 5510, CNRS, INSA Lyon, Villeurbanne, France
-
Olivier TILLEMENT: Professor - Institut Lumière Matière, UMR 5306, Université Lyon 1 – CNRS, Université de Lyon, Villeurbanne cedex, France
INTRODUCTION
This article describes the interest of multimodal hybrid nanoparticles (gold, silica, iron oxide and quantum dots nanoparticles) of less than 10 nm for application in oncology. Hybrid nanoparticles can be used as imaging or therapeutic agents for tumor detection and/or treatment. They have the advantage of increasing the signal per object, being able to combine different imaging techniques and being able to target the area of interest, while exhibiting relatively rapid renal elimination.
hybrid nanoparticles (gold, silica and iron oxide based nanoparticles, quantum dots) with a size inferior to 10 nm for applications in oncology will be described in this article. Hybrid nanoparticles can be used as imaging or therapeutic agent for detection and/or therapy of tumors. They display several advantages in comparison with molecular agents : better signal per object, the possibility to combine many functionalities for imaging and/or therapy and the capacity to target the tumor in combination with an adapted biodistribution and a relatively fast renal elimination.
nanoparticles, contrast agents, oncology, state of the art, multimodality, theranostics
nanoparticles, contrast, agent oncology, state of art, multimodality, theranostic
The Ultimate Scientific and Technical Reference
KEYWORDS
nanoparticles | State of the art | contrast agent | multimodality | theranostic
This article is included in
Healthcare technologies
This offer includes:
Knowledge Base
Updated and enriched with articles validated by our scientific committees
Services
A set of exclusive tools to complement the resources
Practical Path
Operational and didactic, to guarantee the acquisition of transversal skills
Doc & Quiz
Interactive articles with quizzes, for constructive reading
Multimodal hybrid nanoprobes for medical applications
Introduction
Bibliography
- (1) - HONG (H.), ZHANG (Y.), SUN (J.), CAI (W.) - « Molecular imaging and therapy of cancer with radiolabelled nanoparticles » - Nano Today, 4, 399-413 (2009).
- (2) - - http://www.omnt.fr/index.php/fr/publication/afficher/38 ...
The Ultimate Scientific and Technical Reference
